

Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis

A significant proportion of patients with rheumatoid arthritis (RA) misses the target of disease remission solely because of the patient global assessment of disease activity (PGA) exceeding the cut-off of 1.¹⁻⁵ As PGA may also reflect non-inflammatory symptoms, its inclusion as a driver of intensification of immunosuppressive therapy is currently being questioned.⁶ Complete omission of the patients' perspective, however, impairs functional outcomes and the ability to discriminate effective treatments from placebo.⁷ As such, different thresholds for the PGA are being tested, with a recent proposal from randomised clinical trials suggesting a suitable cut-off of 2.⁸

Here, we evaluated the performance of modifying the Boolean definition of remission⁹ by increasing the cut-off of the PGA to 2⁸ in real life. Data were retrieved from 826 consecutive patients from two University Hospitals with an observation period of 12 months. Five hundred and thirty-five were patients with early RA (median (IQR) symptoms' duration 16 [9–28] weeks) started on methotrexate aimed at low disease activity.¹⁰ Two hundred and ninety-one were established patients with RA (median (IQR) duration 6.7 [3.4–13.6] years) started on a biological drug (a tumour necrosis factor antagonist in 79.4% of the cases). In early RA, the rates of remission following PGA modification only slightly increased of +4.1% at 6 months and +4.3% at 12 months. Within remitters according to the Simplified Disease Activity Index (SDAI), simultaneous Boolean remitters increased from 65.7% at 6 months and 64.7% at 12 months with the original definition to 81.8% and 85.7% with the modified definition. However, modified Boolean remitters (original Boolean remitters excluded) were in SDAI remission in fewer cases compared with original Boolean remitters (40.9% vs 97.1% and 57.1% vs 96.7% at 6 and 12 months). As such, the concordance with SDAI remission was lower for modified compared with original Boolean remission at both time points (κ statistics 0.35, 95%CI 0.11 to 0.58 vs 0.74, 95%CI 0.67 to 0.82 and 0.52, 95%CI 0.28 to 0.75 vs 0.71, 95%CI 0.64 to 0.78). In contrast, in established RA, the increase in the remission rate was more pronounced (+7.3% and +12.5% at 6 and 12 months), and concordance with SDAI remission was higher compared with early RA (κ statistics 0.63, 95%CI 0.42 to 0.84 and 0.65, 95%CI 0.46 to 0.84 at the two time points). Patients in modified Boolean remission also showed different disease activity characteristics and functional outcomes in relation to disease duration (table 1). Indeed, in early RA, modified Boolean remitters at 6 months had significantly higher levels of C reactive protein (CRP) compared with original Boolean remitters. Furthermore, their Health Assessment Questionnaire (HAQ) at 12 months worsened of a clinically significant mean (SD) of 0.24 (0.31) points compared with functional stability in original Boolean remitters, and an HAQ ≤ 0.5 was observed in fewer cases. In contrast, in established RA, CRP levels, HAQ variations and the rate of good functional outcome (HAQ ≤ 0.5) at 12 months were comparable between modified and original Boolean remitters.

The inclusion of patients from a real-life clinical setting, with different disease duration, activity and treatment protocols hampers any comparison with published studies,⁸ and our observations need confirmation in independent cohorts. However, our data suggest that a cut-off of the PGA of 2 increases the

Table 1 Comparison of disease characteristics and functional outcomes according to the original and the modified definition of remission

	Original Boolean remission	Modified Boolean remission	P value
6 months			
Early RA			
SJC28	0.5 (0.6)	0.6 (0.5)	0.77
TJC28	0.1 (0.4)	0.4 (0.7)	0.08
VAS pain 0–100	3.9 (7.7)	16.7 (7.2)	<0.001
HAQ 0–3	0.11 (0.25)	0.18 (0.30)	0.26
ESR, mm/1 h	13.6 (10)	15.8 (9.9)	0.41
CRP, mg/dL	0.26 (0.22)	0.43 (0.32)	0.01
Established RA			
SJC28	0.1 (0.2)	0.2 (0.6)	0.21
TJC28	0.2 (0.4)	0.3 (0.5)	0.34
VAS pain 0–100	5.8 (6.1)	13.6 (6.8)	<0.001
HAQ 0–3	0.16 (0.27)	0.35 (0.29)	0.007
ESR, mm/1 h	15.7 (12)	19 (13.5)	0.27
CRP, mg/dL	0.32 (0.23)	0.31 (0.25)	0.80
Functional outcomes at 12 months			
Early RA			
HAQ variation from 6 to 12 months	0.02 (0.34) paired t-test p=0.61	0.24 (0.31) paired t-test p=0.004	0.02
HAQ ≤ 0.5	93%	72.2%	0.05
Established RA			
HAQ variation from 6 to 12 months	0.02 (0.26) paired t-test p=0.56	-0.09 (0.29) paired t-test p=0.20	0.12
HAQ ≤ 0.5	88.1%	88.9%	0.75

Data are reported as means and SD unless otherwise stated.

Data are shown for non-overlapping remission groups. That is, the group in modified Boolean remission does not include patients in original Boolean remission.

Bold indicates statistically significant p values ($p < 0.5$).

CRP, C reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis; SJC28, swollen joint count on 28 joints; TJC28, tender joint count on 28 joints; VAS, Visual Analogue Scale.

rates of remission without impacting on outcomes in patients with established RA. In contrast, in early disease, before changes in pain processing mechanisms have occurred,¹¹ the PGA may more strictly collect information on inflammatory-related symptoms, and even small increases of its cut-off may affect functional outcomes. Better understanding of the relationship between patient-reported outcomes and disease activity in the various phases of RA may thus be needed before introducing definitive changes in the current definition of remission.

Serena Bugatti ^{1,2}, Ludovico De Stefano,^{1,2} Ennio Giulio Favalli ³, Roberto Caporali,^{3,4} Carlomaurizio Montecucco^{1,2}

¹Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Lombardia, Italy

²Division of Rheumatology, IRCCS S Matteo, Pavia, Lombardia, Italy

³Department of Rheumatology, Gaetano Pini-CTO, Milano, Lombardia, Italy

⁴Department of Clinical Sciences and Community Health, University of Milan, Milano, Lombardia, Italy

Correspondence to Professor Serena Bugatti, Division of Rheumatology, University of Pavia, Pavia 27100, Italy; serena.bugatti@unipv.it

Contributors SB contributed to the conception of the work, to the analysis and interpretation of data and to the drafting of the work. LDS contributed to the acquisition and analysis of data and to the drafting of the work. EGF contributed to the acquisition and interpretation of data and revised the manuscript critically. RC revised the manuscript critically for important intellectual content. CM contributed to the conception of the work and revised the manuscript critically for important intellectual content. All the authors provided final approval of the version to be published.

Funding This study was supported in part by fundings from the IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval IRCCS Policlinico San Matteo Foundation Ethics Committee n.20070001302. ASST Gaetano Pini-CTO Institute Ethics Committee

Provenance and peer review Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Bugatti S, De Stefano L, Favalli EG, *et al.* *Ann Rheum Dis* 2022;**81**:e55.

Received 2 April 2020

Accepted 3 April 2020

Published Online First 20 April 2020



► <http://dx.doi.org/10.1136/annrheumdis-2020-217705>

Ann Rheum Dis 2022;**81**:e55. doi:10.1136/annrheumdis-2020-217488

ORCID iDs

Serena Bugatti <http://orcid.org/0000-0002-5396-7077>

Ennio Giulio Favalli <http://orcid.org/0000-0003-1471-6467>

REFERENCES

- 1 Studenic P, Smolen JS, Aletaha D. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. *Ann Rheum Dis* 2012;71:1702–5.
- 2 Vermeer M, Kuper HH, van der Bijl AE, *et al.* The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion. *Rheumatology* 2012;51:1076–80.
- 3 Ferreira RJO, Dougados M, Kirwan JR, *et al.* Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. *Rheumatology* 2017;56:1573–8.
- 4 Ferreira RJO, Duarte C, Ndosi M, *et al.* Suppressing inflammation in rheumatoid arthritis: does patient global assessment blur the target? A practice-based call for a paradigm change. *Arthritis Care Res* 2018;70:369–78.
- 5 Ferreira RJO, Carvalho PD, Ndosi M, *et al.* Impact of patient's global assessment on achieving remission in patients with rheumatoid arthritis: a multinational study using the Meteor database. *Arthritis Care Res* 2019;71:1317–25.
- 6 Ferreira RJO, Ndosi M, de Wit M, *et al.* Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis. *Ann Rheum Dis* 2019;78:e109.
- 7 Aletaha D, Landewe R, Karonitsch T, *et al.* Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. *Ann Rheum Dis* 2008;67:1360–4.
- 8 Studenic P, Felson D, de Wit M, *et al.* Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal? *Ann Rheum Dis* 2020;79:445–52.
- 9 Felson DT, Smolen JS, Wells G, *et al.* American College of Rheumatology/European League against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. *Ann Rheum Dis* 2011;70:404–13.
- 10 Balduzzi S, Scirè CA, Sakellariou G, *et al.* In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: comparison of two cohorts treated according to different treat-to-target protocols. *Clin Exp Rheumatol* 2017;35:401–5.
- 11 Lee YC, Lu B, Boire G, *et al.* Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. *Ann Rheum Dis* 2013;72:949–54.